iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
June 22, 2020 09:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020 EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced...
iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
June 15, 2020 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020 Cambridge, MA and Gosselies, Belgium – June 15,...
iTeos Therapeutics Strengthens Leadership Team
June 09, 2020 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Strengthens Leadership Team Matthew Gall joins as Chief Financial OfficerDr. Yvonne McGrath joins as Vice President of R&DPhilippe Brantegem joins as Vice President of Human...
iTeos Therapeutics Strengthens Leadership Team
June 09, 2020 01:01 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Strengthens Leadership Team Matthew Gall joins as Chief Financial OfficerDr. Yvonne McGrath joins as Vice President of R&DPhilippe Brantegem joins as Vice President of Human...
iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors
June 01, 2020 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors Cambridge, MA and Gosselies, Belgium – June 1, 2020 – iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the...
iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors
June 01, 2020 01:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors Cambridge, MA and Gosselies, Belgium – June 1, 2020 – iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the...
iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
April 27, 2020 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020 – Initial data from the dose escalation portion of the Phase 1/2a trial in 21...
iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
April 27, 2020 01:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020 – Initial data from the dose escalation portion of the Phase 1/2a trial in 21...
iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
April 20, 2020 07:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020 Gosselies, Belgium and Cambridge, MA – April 20,...
iTeos Therapeutics Closes $125 Million Series B2 Financing
April 01, 2020 12:06 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Closes $125 Million Series B2 Financing - Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and...